CRAYON
Every story · every side  ·  est. 1995
Business

Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

CRAYON summary

CNBC reports that Novartis has raised its peak sales forecasts for its blockbuster drugs to $18 billion as the drugmaker seeks to show its growth can last. According to CNBC, the company cited strong demand as it upgraded forecasts for its multiple sclerosis, leukemia and cholesterol medicines.

Based on CNBC's report - only one outlet has covered this so far. Read the original.
▲ Sign in to vote stories up

Coverage 1 source · 1 report

Chronological.

  1. CNBC FIRST 2h ago Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

    The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.

Discussion 0 comments